Goldman Sachs Group Inc
Change company Symbol lookup
Select an option...
GS Goldman Sachs Group Inc
FSGRX Franklin Small Cap Growth Fund Class A
IVR-B Invesco Mortgage Capital Inc
EWBC East West Bancorp Inc
RVNC Revance Therapeutics Inc
ZFGN Zafgen Inc
SFOR StrikeForce Technologies Inc
SPLV Invesco S&P 500® Low Volatility ETF
USMV iShares Edge MSCI Min Vol USA ETF
HULYX Hawaiian Tax-Free Trust Class Y
Go

Financials : Capital Markets | Large Cap ValueCompany profile

The Goldman Sachs Group, Inc. is an investment banking, securities and investment management company that provides a range of financial services to corporations, financial institutions, governments and individuals. The Company operates in four business segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Management. The Investment Banking segment consists of financial advisory and underwriting. The Institutional Client Services segment makes markets and facilitates client transactions in fixed income, equity, currency and commodity products. The investing and lending activities, which are typically longer-term, include its investing and relationship lending activities across various asset classes, primarily debt securities and loans, public and private equity securities, infrastructure and real estate. The Investment Management segment provides investment and wealth advisory services. As of December 2016, it had offices in over 30 countries.

Closing Price
$196.20
Day's Change
-6.22 (-3.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
201.88
Day's Low
195.19
Volume
(Heavy Day)
Volume:
2,201,526

10-day average volume:
1,826,450
2,201,526

UPDATE: Cannabis stocks rally with Aleafia leading the charge after a capital raise

11:11 am ET June 29, 2019 (MarketWatch)
Print

By Ciara Linnane, MarketWatch

Zenabis gains after GMP starts coverage with a buy rating and Village Farms boosted by separate bullish GMP note

Cannabis stocks rose Thursday, led by Aleafia Health Inc., which rallied after announcing the closure of a $40. 25 million convertible debt offering that will bolster its balance sheet and help grow its business.

Toronto-based Aleafia's U.S.-listed shares were last up about 14% in heavier-than-average volume to mark their biggest one-day percentage gain since September 21. The company said the underwriters on its debt offering, Mackie Research Capital, BMO Capital Markets and Cannacord Genuity Corp., fully exercised the over-allotment option to contribute $5.25 million to the total raised. More than 793,000 shares had changed hands by midday, exceeding the average daily volume of 579,000.

Market leader Canopy Growth Corp. shares (WEED.T) rose 1.5%, after the company said it has implemented its arrangement with Acreage Holdings Inc. , the U.S. multistate operator that Canopy has an option to acquire as soon as U.S. federal laws on cannabis have been relaxed. Acreage shareholders will receive about $2.63 per share as part of the $300 million that Canopy is paying for that option by July 3.

Acreage will continue to be run independently, but will have access to Canopy's IP and brands, product formulation and patents.

Don't miss: Money flows in 17 popular marijuana stocks show fewer 'short squeezes' (http://www.marketwatch.com/story/money-flows-in-17-popular-marijuana-stocks-show-fewer-short-squeezes-2019-06-26)

"This arrangement supplements and amplifies Canopy's ability to attack the U.S., the largest global cannabis market ($100 billion opportunity by our estimate) providing a significant competitive advantage for Canopy in relation to its Canadian peers," Stifel analysts led by Andrew Carter wrote last week in a note to clients.

Zenabis Global Inc. shares (ZENA.T) rose 3%, after GMP initiated coverage of the stock with a buy rating and C$3.25 ($2.48) stock price target that is almost double its current trading level. Analysts led by Justin Keywood said the company has the opportunity to become a top five supplier, but its valuation still lags peers.

"We spoke to several of ZENA's partners, including government contacts who all had exceptional regard for the company and its products," Keywood wrote in a note to clients. "ZENA's quality of facilities, receptiveness of management and ethical practices were all mentioned as key criteria in a stringent partner evaluation process."

The stock has suffered from the overhang caused by an open convertible bond, but is looking oversold given some coming catalysts, he wrote. "As ZENA continues to execute on its growth plan, the financing overhang dissipates and a solid partner ecosystem expands, we expect valuation to re-rate higher."

Village Farms International Inc. shares (VFF.T) rose 1.4%, after a separate note from GMP on its joint venture with Pure Sunfarms in British Columbia. Analyst Andrew Partheniou said he came away from a visit with Pure Sunfarms confident in management's ability to transform the venture from a B2B wholesaler to other licensed players to a sales mix that is mostly generated from provincial governments.

"Furthermore, we gleaned greater insight into PSF's industry-leading margin profile and believe the JV can maintain its leadership position," the analyst wrote. With Village Farms trading at a roughly 25% discount to peers, it's time to buy the stock, said the note. GMP rates the company a buy and has a C$25.50 price target that is about 72% above its current trading level.

In regulatory news, New Hampshire Gov. Chris Sununu vetoed a law that would have opened the state's medical cannabis business to for-profit businesses, as Marijuana Business Daily reported (https://mjbizdaily.com/new-hampshire-governor-nixes-for-profit-cannabis-firms/). The news is a blow for entrepreneurs hoping to start a business there. New Hampshire medical cannabis businesses are obliged to operate as non-profits.

From Massachusetts comes the news that regulators have given preliminary approval to rules for cannabis cafes and delivery services, expanding the business there to new areas, the Boston Globe reported (https://www.bostonglobe.com/news/marijuana/2019/06/25/regulators-inch-closer-approving-marijuana-delivery-cafes/IEpPSc4a0Sf8P9yyvNi9QI/story.html). The rules, which are expected to be finalized by September, would favor licenses for local entrepreneurs with small business that already have microbusiness or craft-cooperative licenses, and participants in social equity programs, the paper reported.

The thorny issue of CBD regulation resurfaced Wednesday, when Senator Ron Wyden, a Democrat from Oregon, said it is "fully unacceptable" for the Food and Drug Administration to say it may take up to five years to issue rules on adding hemp-derived CBD to food, as advocacy site Marijuana Moment reported. (https://www.marijuanamoment.net/senator-urges-fda-to-speed-up-cbd-regulations/)

Don't miss:An entire industry is being built around CBD, but we really don't know that much about it (http://www.marketwatch.com/story/an-entire-industry-is-being-built-around-cbd-but-we-really-dont-know-that-much-about-it-2019-05-15)

Hemp was legalized in the 2018 Farm Bill, but CBD, a non-intoxicating ingredient in the plant that is widely held to have wellness benefits, was placed under FDA supervision. That's because CBD is the main ingredient in the only cannabis-based drug to win FDA approval, GW Pharma PLC's Epidiolex, a treatment for severe types of childhood epilepsy.

Wyden said hemp producers stand to benefit from the legalization, but the lack of clarity around CBD was an obstacle.

See:Exclusive: Facebook will not allow marijuana sales on its platform (http://www.marketwatch.com/story/exclusive-facebook-still-will-not-allow-marijuana-sales-to-be-promoted-on-its-platform-2019-05-22)

"The regulatory confusion and uncertainty surrounding CBD cannot continue for that length of time," Wyden wrote in a letter to the heads of the FDA and U.S. Department of Health and Human Services.

Meet:This company wants to be the Bacardi of cannabis -- and it has plans for an IPO (http://www.marketwatch.com/story/this-company-wants-to-be-the-bacardi-of-cannabis-and-it-has-plans-for-an-ipo-2019-05-24)

A swath of companies from the health care, nutritional supplement, beverage and food industries are keen to see CBD regulation that will allow them to unleash a line of products to the market, including creams and topicals, edibles and drinks.

Elsewhere in the sector, Aurora Cannabis Inc. shares (ACB.T) (ACB.T) were up 1.5%, Cronos Group Inc. (CRON.T) was up 0.9% and Tilray Inc. (TLRY) was flat. Hexo Corp. was up 5.5% and Organigram Holdings Inc. (OGI.V) was up 2.2%.

Vape and accessories maker Greenlane Holdings Inc. shares (GNLN) rallied 9.4%.

Aphria shares (APHA.T) (APHA.T) were up 0.7%, Green Growth Brands Inc.was down 0.7% and MedMen Enterprises Inc. was up 4.5%.

Read:How living near a marijuana dispensary affects your home's price (http://www.marketwatch.com/story/on-420-consider-how-living-near-a-marijuana-dispensary-affects-your-homes-price-2019-04-20)

The ETFMG Alternative Harvest ETF (MJ) was up 1% with 29 of its 38 constituent stocks gaining. The Horizons Marijuana Life Sciences ETFwas up 0.8%, with 30 of its 54 constituents trading higher.

The S&P 500 was up 0.3% and the Dow Jones Industrial Average was down 0.1%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 29, 2019 11:11 ET (15:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.